Jason Shand Robins - 20 Jan 2026 Form 3 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Interim CFO
Signature
/s/ Todd Anderman, Attorney-in-Fact for Jason Shand Robins
Issuer symbol
OCUL
Transactions as of
20 Jan 2026
Net transactions value
$0
Form type
3
Filing time
22 Jan 2026, 18:39:37 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Robins Jason Shand Interim CFO C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD /s/ Todd Anderman, Attorney-in-Fact for Jason Shand Robins 22 Jan 2026 0002104600

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OCUL Common Stock 52,656 20 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OCUL Stock Option (Right to Buy) 20 Jan 2026 Common Stock 110,600 $8.12 Direct F2
holding OCUL Stock Option (Right to Buy) 20 Jan 2026 Common Stock 68,195 $11.82 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 20,917 restricted stock units ("RSUs") remaining unvested pursuant to an award of 31,375 RSUs granted under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation") on January 13, 2025, and 22,425 RSUs remaining unvested pursuant to an award of 22,425 RSUs granted under the Corporation's 2021 Stock Incentive Plan, as amended, on January 2, 2026. Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the respective date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2 This option was granted on January 13, 2025 and vests over four years, with 25% of the original number of shares vesting on January 13, 2026 and the remainder vesting in equal monthly installments over the three years after such date.
F3 This option was granted on January 2, 2026 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.

Remarks:

Exhibit Index. Exhibit 24 - Power of Attorney